[Comment] Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality

Immunomodulatory therapies targeting excessive host immune responses,1 vaccination, and immunity from natural infection have changed the course of the COVID-19 pandemic. However, the rapid emergence of SARS-CoV-2 variants has stymied progress towards ending the pandemic. An unmet need remains for accessible therapies that reduce mortality. In The Lancet, the RECOVERY Collaborative Group assessed the use of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of patients hospitalised with COVID-19, in the randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]).